| ￥3300 | |
| Z05723-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
>?95%?as?determined?by?Bis?Tris?PAGE? >?95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 53.1 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 78-98 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Osteoactivin/GPNMB, His, Human is greater than 95% as determined by SEC-HPLC. ?
Osteoactivin/GPNMB, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. ?
| Target Background | GPNMB is highly expressed in macrophages and microglia, which are cells involved with innate immune response in the periphery and the brain, respectively. Some studies have shown increased levels of GPNMB in pro-inflammatory conditions, such as LPS treatment, and in pathological conditions, such as neurodegenerative diseases and cancer. |
| Synonyms | GPNMB; HGFIN; NMB; Osteoactivin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
